美国 · SEC FORM 4
NOVAVAX INC
NVAX · Nasdaq · CIK 0001000694 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
7 同一窗口内观察到的 Form 4 交易行
0 sales · 7 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-03-10 · Glenn Gregory M.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 46,046,946
- 上期报告
- 49,875,210
- 日均成交量
- 5,714,870
- 回补天数
- 8.1
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-03-10 | Glenn Gregory M | 买入 (P) | Common Stock | 1,000 | USD 6.50 | USD 6,500 | SEC 申报 ↗ |
| 2023-03-07 | Glenn Gregory M | 买入 (P) | Common Stock | 2,000 | USD 7.04 | USD 14,080 | SEC 申报 ↗ |
| 2023-03-06 | Glenn Gregory M | 买入 (P) | Common Stock | 3,000 | USD 7.48 | USD 22,440 | SEC 申报 ↗ |
| 2021-05-19 | King Rachel K. | 买入 (P) | Common Stock | 700 | USD 139.64 | USD 97,748 | SEC 申报 ↗ |
| 2020-06-03 | YOUNG JAMES F | 买入 (P) | Common Stock | 1,500 | USD 48.83 | USD 73,245 | SEC 申报 ↗ |
| 2020-01-31 | Glenn Gregory M | 买入 (P) | Common Stock | 1,250 | USD 3.86 | USD 4,825 | SEC 申报 ↗ |
Form 4 申报证据
37 transaction lines in the latest 365-day window; 1,233 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-20 | Rodgers Richard J | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | MOTT DAVID M | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | MCGLYNN MARGARET G | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-20 | Rodgers Richard J | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | MOTT DAVID M | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | MCGLYNN MARGARET G | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | King Rachel K. | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | DOUGLAS RICHARD | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | Alton Gregg H | 期权行权/转换 (M) | Common Stock | 18,880 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-25 | Newton Charles W. | 期权行权/转换 (M) | Common Stock | 9,520 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-10 | Shiver John W. | 期权行权/转换 (M) | Common Stock | 7,947 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-07 | Kelly James Patrick | 期权行权/转换 (M) | Common Stock | 12,223 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-07 | Kelly James Patrick | 代扣税 (F) | Common Stock | 5,904 | USD 9.98 | USD 58,922 | SEC 申报 ↗ |
| 2026-03-03 | O'Hara Elaine | 期权行权/转换 (M) | Common Stock | 56,334 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-03 | O'Hara Elaine | 代扣税 (F) | Common Stock | 22,429 | USD 9.49 | USD 212,851 | SEC 申报 ↗ |
| 2026-03-03 | Kelly James Patrick | 期权行权/转换 (M) | Common Stock | 43,167 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-03 | Kelly James Patrick | 代扣税 (F) | Common Stock | 20,850 | USD 9.49 | USD 197,866 | SEC 申报 ↗ |
| 2026-03-03 | Jacobs John C | 期权行权/转换 (M) | Common Stock | 150,167 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-03 | Jacobs John C | 代扣税 (F) | Common Stock | 69,288 | USD 9.49 | USD 657,543 | SEC 申报 ↗ |
| 2026-03-03 | Draghia-Akli Ruxandra | 期权行权/转换 (M) | Common Stock | 26,667 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-03 | Draghia-Akli Ruxandra | 代扣税 (F) | Common Stock | 11,313 | USD 9.49 | USD 107,360 | SEC 申报 ↗ |
| 2026-03-03 | Casey Mark J | 期权行权/转换 (M) | Common Stock | 37,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-03 | Casey Mark J | 代扣税 (F) | Common Stock | 11,378 | USD 9.49 | USD 107,977 | SEC 申报 ↗ |
| 2026-03-01 | O'Hara Elaine | 期权行权/转换 (M) | Common Stock | 59,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | O'Hara Elaine | 代扣税 (F) | Common Stock | 16,344 | USD 10.14 | USD 165,728 | SEC 申报 ↗ |
| 2026-03-01 | Kelly James Patrick | 期权行权/转换 (M) | Common Stock | 58,666 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Kelly James Patrick | 代扣税 (F) | Common Stock | 28,366 | USD 10.14 | USD 287,631 | SEC 申报 ↗ |
| 2026-03-01 | Jacobs John C | 期权行权/转换 (M) | Common Stock | 83,333 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Jacobs John C | 代扣税 (F) | Common Stock | 38,450 | USD 10.14 | USD 389,883 | SEC 申报 ↗ |
| 2026-03-01 | Casey Mark J | 期权行权/转换 (M) | Common Stock | 4,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Casey Mark J | 代扣税 (F) | Common Stock | 1,214 | USD 10.14 | USD 12,310 | SEC 申报 ↗ |
| 2026-01-23 | Jacobs John C | 期权行权/转换 (M) | Common Stock | 83,197 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-23 | Jacobs John C | 代扣税 (F) | Common Stock | 39,132 | USD 9.17 | USD 358,840 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NVAX |
| CIK | 0001000694 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 1,233 transaction lines from 2020-01-31 to 2026-06-20 6 P purchase lines · 795 S sale lines · 432 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.